Patent ID: 8252905

Claim:
A fusion protein comprising (I) an anti-CD14 antibody or its CD14 binding fragment, wherein said antibody or the fragment has an antigen binding activity and an inhibitory activity for LPS-induced IL-6 production in a TLR expressing cell, and (II) an inhibitor for a protease recited in 1) or 2) below; 1) a polypeptide consisting of any one of amino acid sequences selected from the group consisting of a human UTI domain 2 (hereinafter referred to “UTI-D2”) represented by from 474th to 543rd amino acid residues of SEQ ID NO 10 and a mutant of human UTI domain 2 with 3 amino acid substitutions (R11S/Q19K/Y46D) (hereinafter referred to “UTI-D2(3)”) represented by from 474th to 543rd amino acid residues of SEQ ID NO 12, 2) a mutant of UTI-D2, wherein the mutant has one or more mutations, and wherein the one or more mutations are selected from the group consisting of: a deletion of the 474 th amino acid of SEQ ID NO: 10, a deletion of the 475 th amino acid of SEQ ID NO: 10, a substitution of the 484 th amino acid of SEQ ID NO: 10, a substitution of the 492 nd amino acid of SEQ ID NO: 10, and a substitution of the 519 th amino acid of SEQ ID NO: 10 to the amino acid sequence recited in 1) above, wherein said mutant has an anticoagulant action, or an inhibitory action for a blood coagulation factor.